Page last updated: 2024-08-17

levodopa and moclobemide

levodopa has been researched along with moclobemide in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (11.11)	18.7374
1990's	2 (22.22)	18.2507
2000's	3 (33.33)	29.6817
2010's	1 (11.11)	24.3611
2020's	2 (22.22)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Bizière, K; Kan, JP; Roncucci, R; Wermuth, CG; Worms, P	1
Channon, S; Lees, AJ; Ramponi, C; Sieradzan, K; Stern, GM; Youdim, MB	1
Barbanti, P; Bramante, L; DePandis, F; Fabbrini, G; Manfredi, M; Ruggieri, S; Stocchi, F; Vacca, L	1
Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG	2

Trials

2 trial(s) available for levodopa and moclobemide

Article	Year
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:4 Suppl 2 Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Parkinson Disease; Psychomotor Performance	1995
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Advances in neurology, 1996, Volume: 69 Topics: Antiparkinson Agents; Benzamides; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease	1996

Article

Year

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.

Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:4 Suppl 2

Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Parkinson Disease; Psychomotor Performance

1995

An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.

Advances in neurology, 1996, Volume: 69

Topics: Antiparkinson Agents; Benzamides; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease

1996

Other Studies

7 other study(ies) available for levodopa and moclobemide

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. The Journal of pharmacology and experimental therapeutics, 1987, Volume: 240, Issue:1 Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Body Temperature; Catalepsy; Clorgyline; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Nomifensine; Oxotremorine; Pargyline; Piperidines; Pyridazines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stereotyped Behavior	1987
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders	2020
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced	2020